S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
NASDAQ:TLIS

Talis Biomedical (TLIS) Stock Price, News & Analysis

$8.16
-0.02 (-0.24%)
(As of 03/1/2024 ET)
Today's Range
$7.87
$8.29
50-Day Range
$7.20
$8.88
52-Week Range
$4.35
$9.19
Volume
14,307 shs
Average Volume
10,872 shs
Market Capitalization
$14.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Talis Biomedical MarketRank™ Stock Analysis

Analyst Rating
Sell
1.00 Rating Score
Upside/​Downside
38.7% Downside
$5.00 Price Target
Short Interest
Healthy
0.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Talis Biomedical in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.61 out of 5 stars

Medical Sector

875th out of 950 stocks

Analytical Instruments Industry

25th out of 26 stocks


TLIS stock logo

About Talis Biomedical Stock (NASDAQ:TLIS)

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also develops Talis One tests for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B. The company was incorporated in 2013 and is headquartered in Redwood, California.

TLIS Stock Price History

TLIS Stock News Headlines

TLIS Feb 2024 2.500 put
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
LICY, BTAI and HROW among mid-day movers
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
A Preview Of Talis Biomedical's Earnings
TLIS - Talis Biomedical Corporation
Talis Biomedical reports Q1 results
See More Headlines
Receive TLIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/15/2022
Today
3/02/2024
Next Earnings (Estimated)
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TLIS
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
-38.7%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$-113,010,000.00
Net Margins
-3,436.98%
Pretax Margin
-3,436.98%

Debt

Sales & Book Value

Annual Sales
$4.81 million
Book Value
$70.95 per share

Miscellaneous

Free Float
983,000
Market Cap
$14.84 million
Optionable
No Data
Beta
1.71
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Robert Kelley MBA (Age 52)
    CEO & Director
    Comp: $1.05M
  • Dr. Rustem F. Ismagilov Ph.D. (Age 50)
    Co-Founder & Director
    Comp: $75.36k
  • Dr. Andrew A. Lukowiak Ph.D. (Age 52)
    President & Chief Scientific Officer
  • Mr. Liang Li Ph.D.
    Co-Founder and Director of Technology & Strategy
  • Ms. Rebecca Markovich (Age 51)
    Interim Chief Financial Officer
  • Ms. Emily Faucette
    Senior Vice President of Corporate Communications & Investor Relations
  • Ms. Jill Green
    Senior Vice President of Legal
  • Mr. Matthew Pepe
    Vice President of Human Resource
  • Ms. Margaret Barrett M.S.
    Controller
  • Gillian Green
    Company Secretary














TLIS Stock Analysis - Frequently Asked Questions

Should I buy or sell Talis Biomedical stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Talis Biomedical in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" TLIS shares.
View TLIS analyst ratings
or view top-rated stocks.

What is Talis Biomedical's stock price target for 2024?

1 equities research analysts have issued 12-month price objectives for Talis Biomedical's shares. Their TLIS share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests that the stock has a possible downside of 38.7%.
View analysts price targets for TLIS
or view top-rated stocks among Wall Street analysts.

How have TLIS shares performed in 2024?

Talis Biomedical's stock was trading at $7.45 on January 1st, 2024. Since then, TLIS shares have increased by 9.5% and is now trading at $8.1563.
View the best growth stocks for 2024 here
.

Are investors shorting Talis Biomedical?

Talis Biomedical saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 14,200 shares, a decline of 22.4% from the January 31st total of 18,300 shares. Based on an average daily volume of 10,800 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.9% of the company's shares are short sold.
View Talis Biomedical's Short Interest
.

When is Talis Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our TLIS earnings forecast
.

How were Talis Biomedical's earnings last quarter?

Talis Biomedical Co. (NASDAQ:TLIS) issued its earnings results on Tuesday, March, 15th. The company reported ($18.90) EPS for the quarter, beating analysts' consensus estimates of ($19.20) by $0.30. Talis Biomedical had a negative trailing twelve-month return on equity of 72.82% and a negative net margin of 3,436.98%.

When did Talis Biomedical's stock split?

Shares of Talis Biomedical reverse split on the morning of Thursday, July 6th 2023. The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Talis Biomedical IPO?

(TLIS) raised $150 million in an initial public offering on Friday, February 12th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager.

Who are Talis Biomedical's major shareholders?

Talis Biomedical's stock is owned by a number of institutional and retail investors. Top institutional investors include BML Capital Management LLC (2.35%), Citadel Advisors LLC (0.55%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bros Advisors Lp Baker and Randal W Scott.
View institutional ownership trends
.

How do I buy shares of Talis Biomedical?

Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TLIS) was last updated on 3/3/2024 by MarketBeat.com Staff